News & Events
< Back to News Overview
Peplin Announces Executive Management Appointments
18 / 08 / 2008
Peplin, Inc. (ASX:PLI) announced today that Tom Wiggans has been appointed Chief Executive Officer effective immediately. Mr Wiggans is currently Chairman of Peplin's board of directors and will also continue in that role.
Prior to joining Peplin, Tom Wiggans served as Chairman of the Board and Chief Executive Officer of Connetics Corporation, one of the leading dermatology companies in the United States. Mr Wiggans left this role in December 2006 when Connetics was acquired by Stiefel Laboratories.
"I accepted the Chairman's role last year because I was very impressed with what the company had achieved to-date and the great deal of potential in its lead compound PEP005," said Mr Wiggans. "In the past year there has been momentum building in the development of PEP005 as the company's clinical trial program enters Phase III. I look forward to working with the excellent team at Peplin in both Australia and the United States to take the company to the next stage of the development of PEP005 and its commercialisation."
In addition, Eugene Bauer M.D. has been appointed President and Chief Medical Officer. Dr Bauer was most recently Chief Executive Officer of Neosil Corporation, which has entered into a merger agreement with Peplin. In the role of President and Chief Medical Officer he will be a member of the executive management team, and will be responsible for medical affairs, strategy and communications with key professional constituencies in the U.S. Dr Bauer is currently a non-executive director and will continue as an executive director.
Director and former Chairman Dr Cherrell Hirst said that these appointments were valuable additions to the Peplin executive team as the Company moves into Phase III clinical trials for its lead product PEP005 (ingenol mebutate) for AK,.
"Tom and Gene bring additional proven experience to Peplin''s existing management team in the development and commercialisation of drug candidates in dermatology," Dr Hirst said. "In conjunction with the a very strong cash position following today's announcement of a US$24m capital raising and completion of enrolment in our 240 patient phase IIb US and Australian clinical trial in actinic (solar) keratosis (AK), Peplin is well placed to continue the development of lead product PEP005 (ingenol mebutate) for AK through Phase III trials and towards commercialisation."
Mr Wiggans succeeds Michael Aldridge who has resigned. Mr Aldridge had been CEO since 2003. Dr Hirst paid tribute to the significant progress the company had made during Mr Aldridge's tenure. As CEO, Mr Aldridge oversaw key milestones including securing the Special Protocol Assessment from the US Food and Drug Administration to proceed with Phase III clinical trials for PEP005 (ingenol mebutate) for AK, opening of manufacturing facilities in Southport, Queensland, and the incorporation of Peplin in the United States with the establishment of offices in California.
About Tom Wiggans
Mr Wiggans most recently served as Chairman of the Board and Chief Executive Officer of Connetics Corporation, based in Palo Alto, California, until December of 2006 when Connetics was acquired by Stiefel Laboratories for $730m.
From July 1994 to December 2006, Mr Wiggans served as Connetics' Chief Executive Officer. During that period Connetics grew from a start up specialty pharmaceutical company to one of the leading dermatology companies in the United States, employing approximately 400 people, with five marketed products and annual revenues approaching $200 million. In October of 2006 Connetics announced that it would be acquired by privately held Stiefel Laboratories of Coral Gables, Florida, and the acquisition closed on December 28, 2006. The combined company is the largest independent dermatology company in the world.
From February 1992 to April 1994, Mr Wiggans served as President and Chief Operating Officer of CytoTherapeutics, a biotechnology company. From 1980 to February 1992, he served in various marketing and management positions with Ares-Serono Group,
Prior to joining Peplin, Tom Wiggans served as Chairman of the Board and Chief Executive Officer of Connetics Corporation, one of the leading dermatology companies in the United States. Mr Wiggans left this role in December 2006 when Connetics was acquired by Stiefel Laboratories.
"I accepted the Chairman's role last year because I was very impressed with what the company had achieved to-date and the great deal of potential in its lead compound PEP005," said Mr Wiggans. "In the past year there has been momentum building in the development of PEP005 as the company's clinical trial program enters Phase III. I look forward to working with the excellent team at Peplin in both Australia and the United States to take the company to the next stage of the development of PEP005 and its commercialisation."
In addition, Eugene Bauer M.D. has been appointed President and Chief Medical Officer. Dr Bauer was most recently Chief Executive Officer of Neosil Corporation, which has entered into a merger agreement with Peplin. In the role of President and Chief Medical Officer he will be a member of the executive management team, and will be responsible for medical affairs, strategy and communications with key professional constituencies in the U.S. Dr Bauer is currently a non-executive director and will continue as an executive director.
Director and former Chairman Dr Cherrell Hirst said that these appointments were valuable additions to the Peplin executive team as the Company moves into Phase III clinical trials for its lead product PEP005 (ingenol mebutate) for AK,.
"Tom and Gene bring additional proven experience to Peplin''s existing management team in the development and commercialisation of drug candidates in dermatology," Dr Hirst said. "In conjunction with the a very strong cash position following today's announcement of a US$24m capital raising and completion of enrolment in our 240 patient phase IIb US and Australian clinical trial in actinic (solar) keratosis (AK), Peplin is well placed to continue the development of lead product PEP005 (ingenol mebutate) for AK through Phase III trials and towards commercialisation."
Mr Wiggans succeeds Michael Aldridge who has resigned. Mr Aldridge had been CEO since 2003. Dr Hirst paid tribute to the significant progress the company had made during Mr Aldridge's tenure. As CEO, Mr Aldridge oversaw key milestones including securing the Special Protocol Assessment from the US Food and Drug Administration to proceed with Phase III clinical trials for PEP005 (ingenol mebutate) for AK, opening of manufacturing facilities in Southport, Queensland, and the incorporation of Peplin in the United States with the establishment of offices in California.
About Tom Wiggans
Mr Wiggans most recently served as Chairman of the Board and Chief Executive Officer of Connetics Corporation, based in Palo Alto, California, until December of 2006 when Connetics was acquired by Stiefel Laboratories for $730m.
From July 1994 to December 2006, Mr Wiggans served as Connetics' Chief Executive Officer. During that period Connetics grew from a start up specialty pharmaceutical company to one of the leading dermatology companies in the United States, employing approximately 400 people, with five marketed products and annual revenues approaching $200 million. In October of 2006 Connetics announced that it would be acquired by privately held Stiefel Laboratories of Coral Gables, Florida, and the acquisition closed on December 28, 2006. The combined company is the largest independent dermatology company in the world.
From February 1992 to April 1994, Mr Wiggans served as President and Chief Operating Officer of CytoTherapeutics, a biotechnology company. From 1980 to February 1992, he served in various marketing and management positions with Ares-Serono Group,